TY - JOUR
T1 - Patient's Clinical Presentation and CPPopt Availability
T2 - Any Association?
AU - Liberti, Annalisa
AU - Beqiri, Erta
AU - Ercole, Ari
AU - Cabeleira, Manuel
AU - Tas, Jeanette
AU - Zeiler, Frederick A
AU - Czosnyka, Marek
AU - Smielewski, Peter
AU - Aries, Marcel J
AU - CENTER-TBI High Resolution Substudy Participants and Investigators
N1 - Funding Information:
Acknowledgements The data used here were collected as part of a study supported by the European Union seventh Framework Programme (Grant 602150), Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (Center-TBI).
Funding Information:
Disclosure Authors MC and PS have a financial interest in part of the licensing fees for ICM+ software. MC is supported by NIHR, Biomedical Research Centre, Cambridge, UK.
Publisher Copyright:
© 2021, Springer Nature Switzerland AG.
PY - 2021
Y1 - 2021
N2 - BACKGROUND: The 'optimal' CPP (CPPopt) concept is based on the vascular pressure reactivity index (PRx). The feasibility and effectiveness of CPPopt guided therapy in severe traumatic brain injury (TBI) patients is currently being investigated prospectively in the COGiTATE trial. At the moment there is no clear evidence that certain admission and treatment characteristics are associated with CPPopt availability (yield).OBJECTIVE: To test the relation between patients' admission and treatment characteristics and the average CPPopt yield.METHODS: Retrospective analysis of 230 patients from the CENTER-TBI high-resolution database with intracranial pressure (ICP) measured using an intraparenchymal probe. CPPopt was calculated using the algorithm set for the COGiTATE study. CPPopt yield was defined as the percentage of CPP monitored time (%) when CPPopt is available. The variables in the statistical model included age, admission Glasgow Coma Scale (GCS), gender, pupil response, hypoxia and hypotension at the scene, Marshall computed tomography (CT) score, decompressive craniectomy, injury severity score score and 24-h therapeutic intensity level (TIL) score.RESULTS: The median CPPopt yield was 80.7% (interquartile range 70.9-87.4%). None of the selected variables showed a significant statistical correlation with the CPPopt yield.CONCLUSION: In this retrospective multicenter study, none of the selected admission and treatment variables were related to the CPPopt yield.
AB - BACKGROUND: The 'optimal' CPP (CPPopt) concept is based on the vascular pressure reactivity index (PRx). The feasibility and effectiveness of CPPopt guided therapy in severe traumatic brain injury (TBI) patients is currently being investigated prospectively in the COGiTATE trial. At the moment there is no clear evidence that certain admission and treatment characteristics are associated with CPPopt availability (yield).OBJECTIVE: To test the relation between patients' admission and treatment characteristics and the average CPPopt yield.METHODS: Retrospective analysis of 230 patients from the CENTER-TBI high-resolution database with intracranial pressure (ICP) measured using an intraparenchymal probe. CPPopt was calculated using the algorithm set for the COGiTATE study. CPPopt yield was defined as the percentage of CPP monitored time (%) when CPPopt is available. The variables in the statistical model included age, admission Glasgow Coma Scale (GCS), gender, pupil response, hypoxia and hypotension at the scene, Marshall computed tomography (CT) score, decompressive craniectomy, injury severity score score and 24-h therapeutic intensity level (TIL) score.RESULTS: The median CPPopt yield was 80.7% (interquartile range 70.9-87.4%). None of the selected variables showed a significant statistical correlation with the CPPopt yield.CONCLUSION: In this retrospective multicenter study, none of the selected admission and treatment variables were related to the CPPopt yield.
KW - Brain Injuries, Traumatic/therapy
KW - Cerebrovascular Circulation
KW - Glasgow Coma Scale
KW - Humans
KW - Intracranial Pressure
KW - Retrospective Studies
U2 - 10.1007/978-3-030-59436-7_34
DO - 10.1007/978-3-030-59436-7_34
M3 - Article
C2 - 33839840
SN - 0065-1419
VL - 131
SP - 167
EP - 172
JO - Acta Neurochirurgica, Supplement
JF - Acta Neurochirurgica, Supplement
ER -